论文部分内容阅读
目的探讨恩替卡韦对慢性乙型肝炎患者血清γ-干扰素诱导蛋白-10(IP-10)和γ-干扰素诱生单核因子(Mig)水平的影响及临床意义。方法 40例慢性乙型肝炎患者均采用恩替卡韦片口服。采用双抗体夹心酶联合免疫法检测40例患者治疗前和治疗后3、6个月血清IP-10、Mig水平,采用电化学发光法检测40例患者治疗前和治疗后3、6个月血清乙型肝炎表面抗原(HBs Ag)、乙型肝炎e抗原(HBe Ag)水平,采用荧光定量PCR(FQ-PCR)法检测40例患者治疗前和治疗后3、6个月血清HBV DNA水平,同时进行相关性分析。结果 40例患者治疗后3、6个月血清IP-10、Mig和HBs Ag、HBe Ag、HBV DNA水平均明显低于治疗前(P均<0.05);与治疗后3个月比较,治疗后6个月以上指标均明显降低(P均<0.05)。相关性分析结果显示,40例患者治疗前血清IP-10、Mig水平与血清HBs Ag、HBe Ag、HBV DNA水平均呈负相关(r=-0.462、-0.787、-0.627、-0.735、-0.654、-0.507,P均<0.05),治疗后3、6个月血清IP-10、Mig水平与血清HBs Ag、HBe Ag、HBV DNA水平均呈正相关(r=0.653、0.841、0.761、0.632、0.783、0.828,P<0.05)。结论恩替卡韦与慢性乙型肝炎患者的IP-10、Mig水平及HBs Ag、HBe Ag、HBV DNA水平呈正相关,有积极意义,值得临床推广使用。
Objective To investigate the effect of entecavir on serum levels of interferon-gamma-inducible protein-10 (IP-10) and interferon-gamma-induced mononuclear factor (Mig) in patients with chronic hepatitis B and its clinical significance. Methods 40 patients with chronic hepatitis B were treated with entecavir tablets orally. Serum levels of IP-10 and Mig in 40 patients before and after treatment were detected by double antibody sandwich enzyme-linked immunosorbent assay (ELISA). The serum levels of IP-10 and Mig in 40 patients before and after treatment were detected by electrochemiluminescence HBsAg and HBe Ag levels in serum of 40 patients before and after treatment were detected by fluorescence quantitative PCR (FQ-PCR) At the same time the correlation analysis. Results The levels of serum IP-10, Mig, HBsAg, HBeAg and HBV DNA in 40 patients were significantly lower than those before treatment (P <0.05) at 3 and 6 months after treatment. Compared with 3 months after treatment, The indexes above 6 months were significantly lower (all P <0.05). Correlation analysis showed that serum IP-10 and Mig levels in 40 patients were negatively correlated with serum HBsAg, HBeAg and HBV DNA levels (r = -0.462, -0.787, -0.627, -0.735, -0.654 , -0.507, P <0.05). Serum levels of IP-10 and Mig at 3 and 6 months after treatment were positively correlated with serum HBsAg, HBe Ag and HBV DNA levels (r = 0.653, 0.841, 0.761, 0.632, , 0.828, P <0.05). Conclusions There is a positive correlation between entecavir and IP-10, Mig levels and HBsAg, HBeAg and HBV DNA levels in patients with chronic hepatitis B, which is of great significance and worthy of clinical application.